Version 2 2025-10-30, 02:00Version 2 2025-10-30, 02:00
Version 1 2025-08-27, 03:22Version 1 2025-08-27, 03:22
journal contribution
posted on 2025-10-30, 02:00authored byE Vieta, RS McIntyre, T Suppes, TE Van Rheenen, B Singh, KW Miskowiak, AH Young, LN Yatham, K Ha, Michael BerkMichael Berk, HA Swartz, C Henry, MP Stefanovic, GA Diaz, A Ozerdem, WJ Cubała, D Hidalgo-Mazzei, M Tohen, I Pacchiarotti, PV Nunes, C Lopez-Jaramillo, A Gonzalez-Pinto, P Brambilla, R Post, JC Soares, M Bauer, AC Andreazza, XJ Fradera, M Cosials-Lopez, G Fico
Defining Treatment-Resistant Bipolar Depression: Recommendations From the ISBD Task Force
Funding
Funder: Johnson and Johnson
Funder: Rebecca L. Cooper Medical Research Foundation
Funder: Canadian Institutes of Health Research
Funder: National Center for Advancing Translational Sciences
Funder: Otsuka Pharmaceutical Development and Commercialization Inc
Funder: Mayo Clinic
Funder: Novo Nordisk AS
Funder: Sanofi Aventis US LLC
Funder: Pfizer Inc
Funder: Sunovion Pharmaceuticals Inc
Funder: AbbVie Inc
Funder: Federal Ministry of Education and Research
Funder: Deutsche Forschungsgemeinschaft
Funder: H Lundbeck AS
Funder: National Natural Science Foundation of China